Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth Garrett-Mayer

Showing results (201-210 of 275) with videos related to

Pageof 28
Sort By:
Cancer Immunology, Immunotherapy : CII|February 5, 2016
TCR gene-modified T cells can efficiently treat established hepatitis C-associated hepatocellular carcinoma tumorsTimothy T Spear, Glenda G Callender, Jeffrey J Roszkowski, et al.
JCO Precision Oncology|February 1, 2022
Palbociclib in Patients With Pancreatic and Biliary Cancer With <i>CDKN2A</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry StudyTareq Al Baghdadi, Susan Halabi, Elizabeth Garrett-Mayer, et al.
Breast Cancer Research and Treatment|April 17, 2013
Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancerMichelle A Rudek, Roisin M Connolly, Janelle M Hoskins, et al.
Blood|November 4, 2006
A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemiaJeffrey E Lancet, Ivana Gojo, Jason Gotlib, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 21, 2006
Graft-versus-host reactions and the effectiveness of donor lymphocyte infusionsCarol Ann Huff, Ephraim J Fuchs, B Douglas Smith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 6, 2010
K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylateB Douglas Smith, Yvette L Kasamon, Jeanne Kowalski, et al.
Cancer|November 24, 2020
A randomized, open-label, phase 2, multicenter trial of gemcitabine with pazopanib or gemcitabine with docetaxel in patients with advanced soft-tissue sarcomaNeeta Somaiah, Brian Andrew Van Tine, Amy E Wahlquist, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 28, 2011
Results of a phase II trial of gemcitabine plus doxorubicin in patients with recurrent head and neck cancers: serum C₁₈-ceramide as a novel biomarker for monitoring responseSahar A Saddoughi, Elizabeth Garrett-Mayer, Uzair Chaudhary, et al.
Science Translational Medicine|October 30, 2015
IL-2Rα mediates temporal regulation of IL-2 signaling and enhances immunotherapyEe W Su, Caitlin J Moore, Samantha Suriano, et al.
Cancer Medicine|December 18, 2021
Defining comprehensive biomarker-related testing and treatment practices for advanced non-small-cell lung cancer: Results of a survey of U.S. oncologistsKathryn F Mileham, Caroline Schenkel, Suanna S Bruinooge, et al.
Pageof 28

Showing results (201-210 of 275) with videos related to

Sort By:
Pageof 28
Cancer Immunology, Immunotherapy : CII|February 5, 2016
TCR gene-modified T cells can efficiently treat established hepatitis C-associated hepatocellular carcinoma tumorsTimothy T Spear, Glenda G Callender, Jeffrey J Roszkowski, et al.
JCO Precision Oncology|February 1, 2022
Palbociclib in Patients With Pancreatic and Biliary Cancer With <i>CDKN2A</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry StudyTareq Al Baghdadi, Susan Halabi, Elizabeth Garrett-Mayer, et al.
Breast Cancer Research and Treatment|April 17, 2013
Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancerMichelle A Rudek, Roisin M Connolly, Janelle M Hoskins, et al.
Blood|November 4, 2006
A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemiaJeffrey E Lancet, Ivana Gojo, Jason Gotlib, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 21, 2006
Graft-versus-host reactions and the effectiveness of donor lymphocyte infusionsCarol Ann Huff, Ephraim J Fuchs, B Douglas Smith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 6, 2010
K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylateB Douglas Smith, Yvette L Kasamon, Jeanne Kowalski, et al.
Cancer|November 24, 2020
A randomized, open-label, phase 2, multicenter trial of gemcitabine with pazopanib or gemcitabine with docetaxel in patients with advanced soft-tissue sarcomaNeeta Somaiah, Brian Andrew Van Tine, Amy E Wahlquist, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 28, 2011
Results of a phase II trial of gemcitabine plus doxorubicin in patients with recurrent head and neck cancers: serum C₁₈-ceramide as a novel biomarker for monitoring responseSahar A Saddoughi, Elizabeth Garrett-Mayer, Uzair Chaudhary, et al.
Science Translational Medicine|October 30, 2015
IL-2Rα mediates temporal regulation of IL-2 signaling and enhances immunotherapyEe W Su, Caitlin J Moore, Samantha Suriano, et al.
Cancer Medicine|December 18, 2021
Defining comprehensive biomarker-related testing and treatment practices for advanced non-small-cell lung cancer: Results of a survey of U.S. oncologistsKathryn F Mileham, Caroline Schenkel, Suanna S Bruinooge, et al.
Pageof 28